NICE - Endorsed Technology Appraisals 2019/2020
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2019/2020
The following technology appraisals have been endorsed during 2019/20. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2020
NICE TA 622 - Sotagliflozin with insulin for treating type 1 diabetes
NICE TA 623 - Patiromer for treating hyperkalaemia
NICE TA 624 - Peginterferon beta-1a for treating relapsing - remitting multiple sclerosis
February 2020
‘Note this guidance has been updated and replaced by TA836 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy, which was endorsed by the DoH in November 2022.’
- This guidance updates and replaces NICE Technology Appraisal TA381, which was endorsed by the DoH in February 2016.
- ‘Note this guidance has been updated and replaced by TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy, endorsed by the DoH in August 2023.’
NICE TA 621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
January 2020
NICE TA 614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
NICE TA 616 - Cladribine for treating relapsing–remitting multiple sclerosis (review of TA493)
- This guidance updates and replaces NICE Technology Appraisal TA493, which was endorsed by the DoH in December 2017.
December 2019
- This guidance partially updates NICE Technology Appraisal TA301, which was endorsed by the DoH in December 2013.
- Note this guidance has been updated and replaced by TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema, endorsed by the DoH in April 2024.
November 2019
NICE TA 605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
NICE TA 606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema
NICE TA 610 - Pentosan polysulfate sodium for treating bladder pain syndrome
NICE TA 611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Note this guidance has been updated and replaced by TA1007 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer, endorsed by the DoH in October 2024
October 2019
NICE TA 599 - Sodium zirconium cyclosilicate for treating hyperkalaemia
‘Note this guidance has been updated and replaced by TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer, which was endorsed by the DoH in March 2022’.
NICE TA 604 - Idelalisib for treating refractory follicular lymphoma
September 2019
‘Note this guidance has been updated and replaced by TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma, which was endorsed by the DoH in July 2022’
NICE TA 593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer - Note this guidance has been updated and replaced by TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy, which was endorsed by the DoH in April 2021
NICE TA 595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis
NICE TA 597 - Dapagliflozin with insulin for treating type 1 diabetes
Note this guidance has been updated and replaced by TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy, endorsed by the DoH in April 2024
August 2019
NICE TA 588 - Nusinersen for treating spinal muscular atrophy
NICE TA 591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant
July 2019
NICE TA 585 - Ocrelizumab for treating primary progressive multiple sclerosis
- For third- or further-line use, please see NICE Technology Appraisal TA171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies, endorsed by DoH in September 2010.
NICE TA 587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma
June 2019
NICE TA 579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Note this guidance has been updated and replaced by TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy, which was endorsed by the DoH in October 2021.
NICE TA 580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer
NICE TA 581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma Note this guidance has been updated and replaced by TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma, which was endorsed by the DoH in April 2022
May 2019
NICE TA 573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple
‘Note this guidance has been updated and replaced by TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma, endorsed by the DoH in June 2023.’
NICE TA 574 - Certolizumab pegol for treating moderate to severe plaque psoriasis
NICE TA 575 - Tildrakizumab for treating moderate to severe plaque psoriasis
NICE TA 577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
‘Note this guidance has been updated and replaced by TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation, which was endorsed by the DoH in July 2022’
- This guidance updates and replaces NICE Technology Appraisal TA166, which was endorsed by the DoH in November 2011.
April 2019
NICE TA 565 - Benralizumab for treating severe eosinophilic asthma
NICE TA 569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
NICE TA 572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
‘Note this guidance has been updated and replaced by TA872 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies, endorsed by the DoH in March 2023.’